These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 23488998)

  • 1. How to design multi-target drugs.
    Korcsmáros T; Szalay MS; Böde C; Kovács IA; Csermely P
    Expert Opin Drug Discov; 2007 Jun; 2(6):799-808. PubMed ID: 23488998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficiency of multi-target drugs: the network approach might help drug design.
    Csermely P; Agoston V; Pongor S
    Trends Pharmacol Sci; 2005 Apr; 26(4):178-82. PubMed ID: 15808341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systems biology approaches and tools for analysis of interactomes and multi-target drugs.
    Schrattenholz A; Groebe K; Soskic V
    Methods Mol Biol; 2010; 662():29-58. PubMed ID: 20824465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knowledgebase for addiction-related genes: is it possible an extrapolation to rational multi-target drug design?
    Espinoza-Fonseca LM
    Bioorg Med Chem; 2008 Oct; 16(20):9346-8. PubMed ID: 18815048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What does systems biology mean for drug development?
    Schrattenholz A; Soskić V
    Curr Med Chem; 2008; 15(15):1520-8. PubMed ID: 18537627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding sites in membrane proteins--diversity, druggability and prospects.
    Adams R; Worth CL; Guenther S; Dunkel M; Lehmann R; Preissner R
    Eur J Cell Biol; 2012 Apr; 91(4):326-39. PubMed ID: 21872966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A series of case studies: practical methodology for identifying antinociceptive multi-target drugs.
    Pang MH; Kim Y; Jung KW; Cho S; Lee DH
    Drug Discov Today; 2012 May; 17(9-10):425-34. PubMed ID: 22269134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Application of CADD on multi-target drug R&D in natural products].
    Qiao LS; Zhang YL
    Zhongguo Zhong Yao Za Zhi; 2014 Jun; 39(11):1951-5. PubMed ID: 25272821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unraveling the molecular targets of natural products: Insights from genomic and proteomic analyses.
    Wong CC; Cheng KW; He QY; Chen F
    Proteomics Clin Appl; 2008 Mar; 2(3):338-54. PubMed ID: 21136838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between rational drug design and drug side effects.
    Wang J; Li ZX; Qiu CX; Wang D; Cui QH
    Brief Bioinform; 2012 May; 13(3):377-82. PubMed ID: 21949217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent progress in biomolecular engineering.
    Ryu DD; Nam DH
    Biotechnol Prog; 2000; 16(1):2-16. PubMed ID: 10662483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomic methods for drug target discovery.
    Sleno L; Emili A
    Curr Opin Chem Biol; 2008 Feb; 12(1):46-54. PubMed ID: 18282485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prediction of multi-target of Aconiti Lateralis Radix Praeparata and its network pharmacology].
    Wu L; Gao X; Wang L; Liu Q; Fan X; Wang Y; Cheng Y
    Zhongguo Zhong Yao Za Zhi; 2011 Nov; 36(21):2907-10. PubMed ID: 22308671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining global and local measures for structure-based druggability predictions.
    Volkamer A; Kuhn D; Grombacher T; Rippmann F; Rarey M
    J Chem Inf Model; 2012 Feb; 52(2):360-72. PubMed ID: 22148551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Multi-target therapeutics and new drug discovery].
    Xu Y; Li XJ
    Yao Xue Xue Bao; 2009 Mar; 44(3):226-30. PubMed ID: 19449518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategy for the development of novel anticancer drugs.
    Saijo N; Tamura T; Nishio K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.
    Lu H; Tonge PJ
    Acc Chem Res; 2008 Jan; 41(1):11-20. PubMed ID: 18193820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2D MI-DRAGON: a new predictor for protein-ligands interactions and theoretic-experimental studies of US FDA drug-target network, oxoisoaporphine inhibitors for MAO-A and human parasite proteins.
    Prado-Prado F; García-Mera X; Escobar M; Sobarzo-Sánchez E; Yañez M; Riera-Fernandez P; González-Díaz H
    Eur J Med Chem; 2011 Dec; 46(12):5838-51. PubMed ID: 22005185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.